Dual action of epigallocatechin-3-gallate in virus-induced cell Injury.
Ahmed MostafaGomaa Mostafa-HedeabHany Abdelfattah ElhadyEsraa Ahmed MohamedAbozer Y EledrderySager Holyl AlruwailiAhmed Mohamed Al-AbdAbdou Kamal AllayehPublished in: Journal, genetic engineering & biotechnology (2023)
The EGCG has proven to be an efficient antiviral against SARS-CoV-2 and HSV-2, as well as a wound-healing phytochemical. We assume that EGCG may be a promising option for slowing the course of acute cellular damage induced by systemic (Coronavirus Disease 2019 (COVID-19)) or topical (HSV-2) viral infections.
Keyphrases
- sars cov
- coronavirus disease
- wound healing
- respiratory syndrome coronavirus
- drug induced
- herpes simplex virus
- liver failure
- high glucose
- single cell
- diabetic rats
- oxidative stress
- respiratory failure
- cell therapy
- aortic dissection
- stem cells
- extracorporeal membrane oxygenation
- hepatitis b virus
- bone marrow
- mechanical ventilation